Copper Mountain Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2009
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
XLD - Imaging and Drug Development (C1)
Organizer(s) Lars Farde, Steven M. Larson and Chi-Ming Lee
February 22—26, 2009
Copper Mountain Resort • Copper Mountain, Colorado USA
Abstract Deadline: Oct 21, 2008
Late Abstract Deadline: Nov 21, 2008
Scholarship Deadline: Oct 21, 2008
Early Registration Deadline: Dec 22, 2008
Summary of Meeting:
Positron Emission Tomography (PET) is maturing into a key scientific tool, which is increasingly applied in the scientific community and pharmaceutical industry to study drug distribution, drug-target interactions, and disease processes, especially in CNS and oncology areas. Using specific radiotracers, PET can be performed serially over time in the same live subject to study receptor occupancy and pharmacodynamic response of drug action. These studies can facilitate the selection of drug candidates to advance to clinical trials and guide clinical dose selection. This non-invasive technology also allows longitudinal studies to elucidate the underlying pathophysiology of disease, follow the progression, and monitor the outcome of treatment. The combination of genomic knowledge with PET imaging will provide more specific phenotypes that can help to identify genetic predictors of drug response. The objective of this conference is to bring together a wide range of academic and industrial scientists within the PET molecular imaging community with expertise in imaging systems, analytical tools, and drug discovery/development to address some key issues common to the fields of neurology and oncology. The meeting will provide a forum for the cross-fertilization of experience across these two disciplines, including sharing of knowledge in the development and usage of radiotracers, identifying gaps and opportunities in using PET to facilitate drug development, and discussing innovative solutions to overcome challenges in multi-center trials and biomarker qualification/validation.
View Scholarships/Awards
Positron Emission Tomography (PET) is maturing into a key scientific tool, which is increasingly applied in the scientific community and pharmaceutical industry to study drug distribution, drug-target interactions, and disease processes, especially in CNS and oncology areas. Using specific radiotracers, PET can be performed serially over time in the same live subject to study receptor occupancy and pharmacodynamic response of drug action. These studies can facilitate the selection of drug candidates to advance to clinical trials and guide clinical dose selection. This non-invasive technology also allows longitudinal studies to elucidate the underlying pathophysiology of disease, follow the progression, and monitor the outcome of treatment. The combination of genomic knowledge with PET imaging will provide more specific phenotypes that can help to identify genetic predictors of drug response. The objective of this conference is to bring together a wide range of academic and industrial scientists within the PET molecular imaging community with expertise in imaging systems, analytical tools, and drug discovery/development to address some key issues common to the fields of neurology and oncology. The meeting will provide a forum for the cross-fertilization of experience across these two disciplines, including sharing of knowledge in the development and usage of radiotracers, identifying gaps and opportunities in using PET to facilitate drug development, and discussing innovative solutions to overcome challenges in multi-center trials and biomarker qualification/validation.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, FEBRUARY 22
MONDAY, FEBRUARY 23
TUESDAY, FEBRUARY 24
WEDNESDAY, FEBRUARY 25
THURSDAY, FEBRUARY 26
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, FEBRUARY 22
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.
Steven M. Larson,
Memorial Sloan-Kettering Cancer Center, USA
Molecular Imaging in Drug Discovery for Oncology
Molecular Imaging in Drug Discovery for Oncology
08:00—11:00
Advances in Radiochemistry
Meeting has ended...abstracts no longer viewable online.
Christer Halldin,
Karolinska Institutet, Sweden
Advances in Radiotracer Design and Radiosynthesis of PET Ligands - What are the Remaining Hurdles for Small Molecular Drugs?
Advances in Radiotracer Design and Radiosynthesis of PET Ligands - What are the Remaining Hurdles for Small Molecular Drugs?
Michael R. Zalutsky,
Duke University, USA
Advances in Radiotracer Design and Radiosynthesis of Large Biologicals as PET Ligands - Impact and Future Opportunity
Advances in Radiotracer Design and Radiosynthesis of Large Biologicals as PET Ligands - Impact and Future Opportunity
Joanna Fowler,
Brookhaven National Laboratory, USA
Radiotracer Development and Application in Neuroscience
Radiotracer Development and Application in Neuroscience
Victor Pike,
National Institutes of Health, USA
PET Radiotracers: Facing the Biological Reality - BBB and Metabolic Enzymes
PET Radiotracers: Facing the Biological Reality - BBB and Metabolic Enzymes
Short Talk(s) Chosen from Abstracts
17:00—19:00
Advances in Instrumentation
Meeting has ended...abstracts no longer viewable online.
David W. Townsend,
University of Tennessee Medical Center, USA
Development and Impact of PET/CT - Limits and Future Direction
Development and Impact of PET/CT - Limits and Future Direction
Charles Peck,
IBM T.J. Watson Research Center, USA
Performance Gaps beyond the Imaging Instruments: Advances in Data Acquisition and Analysis
Performance Gaps beyond the Imaging Instruments: Advances in Data Acquisition and Analysis
Short Talk Chosen from Abstracts
08:00—11:00
Molecular Imaging: From Basic to Clinical Research
Meeting has ended...abstracts no longer viewable online.
Lars Farde,
AstraZeneca R&D Södertälje, Sweden
Molecular Imaging in Neuroscience: From Bench to Bedside
Molecular Imaging in Neuroscience: From Bench to Bedside
Marc Laruelle,
GlaxoSmithKline, UK
Early Risk Discharge in CNS Drug Development: The Role of Molecular Imaging
Early Risk Discharge in CNS Drug Development: The Role of Molecular Imaging
Eric O. Aboagye,
Imperial College, UK
Evaluation of PET Radiotracers in Translational Models for Oncology - Limitations and Developments in Animal Models Relevant to Cancer Imaging
Evaluation of PET Radiotracers in Translational Models for Oncology - Limitations and Developments in Animal Models Relevant to Cancer Imaging
Ronald Blasberg,
Memorial Sloan-Kettering Cancer Center, USA
Reporter Gene Imaging Studies in Patients: Issues to Address
Reporter Gene Imaging Studies in Patients: Issues to Address
Short Talk(s) Chosen from Abstracts
14:30—16:30
Workshop 2: Challenges of Multi-Center Trials Using Molecular Imaging
Short Talks Chosen from Abstracts
17:00—19:00
Molecular Imaging of Biological Effects
Meeting has ended...abstracts no longer viewable online.
John Mann,
New York State Psychiatric Institute, USA
PET Imaging in Prediction of Treatment Outcome: Implications for New Drug Development
PET Imaging in Prediction of Treatment Outcome: Implications for New Drug Development
Ingo K. Mellinghoff,
Memorial Sloan-Kettering Cancer Center, USA
Transcriptional Determinants of FDG-PET Retention in Cancer
Transcriptional Determinants of FDG-PET Retention in Cancer
Tetsuya Suhara,
National Institutes for Quantum and Radiological Science and Technology, Japan
Imaging Biomarker for Proof of Concept
Imaging Biomarker for Proof of Concept
Short Talk Chosen from Abstracts
08:00—11:00
Proof of Biological Activity and Mechanism of Action
Meeting has ended...abstracts no longer viewable online.
Anthony Shields,
Wayne State University, USA
The Use of PET to Image Proliferation in Early Oncology Trials - Status and Use in Drug Development & Patient Management
The Use of PET to Image Proliferation in Early Oncology Trials - Status and Use in Drug Development & Patient Management
Julie L. Sutcliffe,
University of California, Davis, USA
Highthroughput Screening of Targeted Molecular Imaging Agents
Highthroughput Screening of Targeted Molecular Imaging Agents
Eric Reiman,
Banner Alzheimer's Institute, USA
Positron Emission Tomography in the Evaluation of Alzheimer’s Disease-Slowing and Prevention Therapies
Positron Emission Tomography in the Evaluation of Alzheimer’s Disease-Slowing and Prevention Therapies
Julie C. Price,
University of Pittsburgh, USA
PET Amyloid Imaging
PET Amyloid Imaging
Short Talk(s) Chosen from Abstracts
14:30—16:30
Workshop 3: Challenges for Biomarker Qualification/Validation
Short Talks Chosen from Abstracts
16:30—19:00
Proof of Concept (Biomarker to Surrogate)
Meeting has ended...abstracts no longer viewable online.
Gary J. Kelloff,
National Cancer Institute, National Institutes of Health, USA
Biomarker Qualification and Validation as a Surrogate in Lymphoma and Lung Cancer - Current Progress and Future Challenges for Use in Drug Development
Biomarker Qualification and Validation as a Surrogate in Lymphoma and Lung Cancer - Current Progress and Future Challenges for Use in Drug Development
Dean F. Wong,
Johns Hopkins Medicine, USA
Neuroreceptor Imaging: Proof of Concept Prebiomarker or Potential Surrogate Marker?
Neuroreceptor Imaging: Proof of Concept Prebiomarker or Potential Surrogate Marker?
Wayne Drevets,
Janssen R&D Pharmaceutical Companies of Johnson & Johnson, USA
Using Molecular Imaging to Identify Phenotypic Differences between Mood Disorder Subtypes
Using Molecular Imaging to Identify Phenotypic Differences between Mood Disorder Subtypes
Short Talk Chosen from Abstracts
*Session Chair †Invited, not yet responded.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
